

Pt. 414-5348
Day 1

M.M.
Matrix Pharmaceutical, Inc. Study MP #414-94-2
Pt # 5348 Pt. Initials
Lesion # 1 Date 7/10/97

Day 1
The patient's tumor measured 13.5 cm^3 on day 1 prior to the first treatment with CDDP/epi gel in the blinded period.

Pt. 414-5348
Day 43

M.M.
Matrix Pharmaceutical, Inc. Study MP #414-94-2
Pt # 5348 Pt. Initials
Lesion # 1 Date 9-3-97

Day 43
On day 43 after five treatments with CDDP/epi gel the MTT regressed to a complete response. Moderate ulceration, necrosis, and erythemia were evident.



Pt. 414-5348
Day 106

M.M.
Matrix Pharmaceutical, Inc. Study MP 414-94-2
Pt # 5348 Pt. Initials
Lesion # 1A Date 11-5-97

Day 106
The complete response was continuing at the last observation on day 106.